Sponsor - U.S. Centers for Disease Control & Prevention (200-2003-01083 / 200-2003-01141 / 200-2009-32598 / 75D30119C06010)
Principal Investigator - John L. Johnson, MD, CWRU
|Type of Study / Description||TB clinical trials at U.S. and international sites - see protocol details below|
|Interactions||Collaborating investigators/staff, utilizing shared infrastructure.|
Overview of the TBTC
The mission of the TBTC is to conduct programmatically relevant clinical, laboratory and epidemiologic research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease. TBTC has sites in the United States, Canada, Brazil, China, Kenya, Peru, Philippines, Spain, South Africa, Uganda, and Vietnam. All sites have close connections with their local TB control program; some sites are based in the TB control program. All sites work with experienced mycobacterial laboratories; the CDC Mycobacteriology Laboratory in Atlanta, GA serves as a central laboratory for confirmation of drug-susceptibility testing, DNA fingerprinting, and further characterization of drug-resistant isolates. Since its inception in 1994 over 11,000 patients have been enrolled in TBTC clinical trials, including several done under Investigational New Drug applications. For further information about TBTC, visit the TBTC website.